Table 2.
Broadly neutralizing antibodies | Target site | Breadth of neutralization (IC50 < 50 μg/mL) |
Study |
---|---|---|---|
VRC01 | CD4 binding site | 89% of 180 isolates | Huang et al. (2012) [32] |
VRC02 | CD4 binding site | 91% of 190 isolates | Wu et al. (2010) [33] |
VRC03 | CD4 binding site | 57% of 190 isolates | Wu et al. (2010) [33] |
VRC-PGV04 | CD4 binding site | 88% of 162 isolates | Walker et al. (2011) [34] |
VRC-PGV04b | CD4 binding site | 71% of 178 isolates | Wu et al. (2011) [35] |
CH103 | CD4 binding site | 55% of 196 isolates | Liao et al. (2013) [22] |
2F5 | gp41 | 39% of 92 isolates | Corti et al. (2010) [36] |
2G12 | gp120 | 41% of 90 isolates | Binley et al. (2004) [37] |
4E10 | gp41 | 98% of 162 isolates | Walker et al. (2009) [38] |
PG9 | V1-V2 loops | 78% of 180 isolates | Huang et al. (2012) [32] |
PGT130 | V3 loop | 52% of 162 isolates | Walker et al. (2011) [34] |
PGT151 | gp120-gp41 | 66% of 117 cross-clade isolates | Bonsignori et al. (2014) [39] |
PGT152 | gp120-gp41 | 64% of 117 cross-clade isolates | Blattner et al. (2014) [40] |
Source: http://www.hiv.lanl.gov/.